Want to join the conversation?
$MRK said that it's planning to submit a supplemental Biologics License Application (sBLA) to the U.S. FDA for KEYTRUDA (pembrolizumab) by the end of 2015 based on the findings from KEYNOTE-010 clinical trial. The company is also intending to submit a Marketing Authorization Application to the European Medicines Agency in early 2016.
Any idea why some investors are happy about the disastrous $UA results??
Wow! GM killed it with earnings today! Did not expect this after $F gave the feeling it will eclipse the Chevy maker completely!
Oil rebound starting to show up in energy stocks. $XOM $CVX
I have a feeling "CLOUDy" days are ahead, with $AMZN leading the pack.
$AAL is giving pay hikes to its employees but investors are sulking.